Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

Power3 Medical Products, Inc. (OTCBB: PWRM - News) announced that four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer's Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro® AD biomarkers and blood test for Alzheimer's disease. The four studies to be presented involve a total of 154 Alzheimer's disease patients and 91 Parkinson's disease patients, as well as 210 age-matched normal control individuals and 173 disease control individuals.

“There will be some surprises for our colleagues at ICAD that we are particularly excited about because they have the potential to guide us towards improvements in treatment for this awful illness.”

The NuroPro® AD biomarkers and blood test are intended to help clinicians distinguish patients with Alzheimer's disease from "normal" individuals, i.e., patients with similar, non-Alzheimer's neurological disorders. They are also intended to solve the critical challenge facing physicians, clinicians, patients and drug developers, who all need tests for early stage accurate and specific diagnosis of this debilitating disease, as well as more guidance for drug therapy, patient selection for drug clinical trials, and better tools to monitor drug treatment response.

The abstracts report the use of combined results from ongoing clinical validation trials of NuroPro® AD. The trials are being conducted by the Power3 scientific team, led by scientific advisory board member Lourdes R. Bosquez, MD and Chief Scientific Officer, Ira L. Goldknopf, Ph.D. in collaboration with Marwan Sabbagh, MD, director of the Banner Sun Health Research Institute. The team is also utilizing previous studies Power3 conducted with Stanley H. Appel, MD during his tenure as Chairman of Neurology at the Baylor College of Medicine and, currently, as Co-Director of the Methodist Neurological Research Institute. Dr. Appel continues to be chairman of the scientific advisory board of Power3.

"These 4 posters represent the culmination of 7 years of hard scientific effort which we have been blessed to pursue with our distinguished collaborators," said Dr. Goldknopf. "There will be some surprises for our colleagues at ICAD that we are particularly excited about because they have the potential to guide us towards improvements in treatment for this awful illness." Dr. Goldknopf will present two of the posters at ICAD, one on NuroPro® AD biomarkers for Alzheimer's specific diagnosis and the other on NuroPro® AD diagnostic clinical validation trials. Dr. Sabbagh will present a third poster on prospective clinical validation of the use of protein biomarkers from newly drawn patient sera for diagnosis of Alzheimer's disease, and Dr. Bosquez will present a fourth poster on NuroPro® AD protein biomarkers and drug response.

"We are proud that Dr. Goldknopf will be joined this year by two members of our scientific advisory board, Dr. Sabbagh and Dr. Bosquez, in presenting to ICAD 2010," said Helen R. Park, MS, Chief Executive Officer of Power3. "For us to present four posters at the same time at such a prestigious forum speaks to the depth of our science and our commitment to improving the outcomes for patients with Alzheimer's disease. This work, in conjunction with the recent filing of our joint patent application with StemTroniX, bodes well for the upcoming acquisition of StemTroniX by Power3."